Identification of a neuronal transcription factor network involved in medulloblastoma development

Łastowska, Maria; Al-Afghani, Hani; Al-Balool, Haya H; Sheth, Harsh; Mercer, Emma; Coxhead, Jonathan M; Redfern, Chris PF; Peters, Heiko; Burt, Alastair D; Santibanez-Koref, Mauro; Bacon, Chris M; Chesler, Louis; Rust, Alistair G; Adams, David J; Williamson, Daniel; Clifford, Steven C; Jackson, Michael S

doi:10.1186/2051-5960-1-35

Acta Neuropathologica Communications

Table 2 CIS gene expression according to clinicogenetic groups and presence of metastatic disease

From: Identification of a neuronal transcription factor network involved in medulloblastoma development

Clinicogenetic groups																			Metastatic disease
		SHH v Other Subgroups				WNT (N=15)			SHH (N=24)			Group 3 (N=24)			Group 4 (N=48)				Mets (N=32)			No Mets (n=75)
		Mean SHH	Mean others	t	p-val	Mean		SE	Mean		SE	Mean		SE	Mean		SE	p-val	Mean		SE	Mean		SE	p-val
NFIA	22497_at	11.25	10.80	-1.31		11.41	±	0.18	11.25	±	0.30	9.44	±	0.42	11.32	±	0.16	**	10.78	±	0.32	11.03	±	0.15
ATXN2	202622_s_at	7.41	7.60	2.00		7.50	±	0.11	7.41	±	0.08	7.36.	±	0.11	7.75	±	0.06	**	7.68	±	0.08	7.47	±	0.05	*
TEAD1	224955_at	10.80	9.85	-6.34	**	11.10	±	0.12	10.80	±	0.12	10.13	±	0.15	9.33	±	0.07	**	9.68	±	0.13	10.11	±	0.11	*
TGIF2	216262_s_at	7.61	5.02	-8.98	***	7.75	±	0.10	7.61	±	0.23	5.48	±	0.28	3.97	±	0.10	**	4.46	±	0.22	5.88	±	0.22	***
CREBBP	202160_at	9.93	9.80	-0.85		9.95	±	0.10	9.93	±	0.10	9.13	±	0.32	10.09	±	0.07	**	9.76	±	0.13	9.82	±	0.12
DSCR3	203635_at	7.08	6.78	-3.19	**	6.84	±	0.18	7.08	±	0.08	6.69	±	0.09	6.80	±	0.06	**	6.82	±	0.08	6.82	±	0.06
PTEN	225363_at	10.31	11.12	4.63	***	11.16	±	0.20	10.31	±	0.15	10.12	±	0.15	11.62	±	0.06	**	11.03	±	0.14	10.94	±	0.10
ITGBL1	214927_at	6.49	3.90	-4.47	***	4.27	±	0.56	6.49	±	0.55	3.16	±	0.25	4.16	±	0.25	**	3.91	±	0.33	4.85	±	0.27	*
NFIB	209290_s_at	12.92	12.67	-0.66		10.46	±	0.48	12.92	±	0.32	12.18	±	0.38	13.58	±	0.09	**	12.81	±	0.28	12.85	±	0.16
MYT1L	210016_at	8.27	10.24	2.80	**	6.06	±	0.70	8.27	±	0.64	9.20	±	0.43	12.02	±	0.11	**	11.28	±	0.22	9.41	±	0.36	**
ANKRD5	220144_s_at	4.63	4.75	0.54		4.51	±	0.28	4.63	±	0.19	5.46	±	0.21	4.46	±	0.10	**	4.65	±	0.16	4.77	±	0.11
SLIT3	203813_s_at	3.01	2.98	-0.17		2.90	±	0.09	3.01	±	0.14	2.82	±	0.05	3.09	±	0.10		2.98	±	0.10	2.94	±	0.06
TMEM45B	226226_at	2.37	2.44	1.57		2.34	±	0.04	2.37	±	0.04	2.52	±	0.04	2.44	±	0.03	*	2.45	±	0.03	2.44	±	0.02
SFI1	36545_s_ar	5.96	5.19	-2.68		5.74	±	0.24	5.96	±	0.25	4.42	±	0.23	5.42	±	0.19	**	5.24	±	0.20	5.36	±	0.16
FGF13	205110_s_at	5.88	8.10	6.66	*	5.33	±	0.86	5.88	±	0.54	6.81	±	0.49	9.58	±	0.16	**	8.73	±	0.39	7.01	±	0.32	**
L3MBTL4	228557_at	6.85	3.73	-7.43	***	4.28	±	0.28	6.85	±	0.40	4.82	±	0.22	3.01	±	0.10	**	3.76	±	0.21	4.59	±	0.24	*
ADCY5	228182_at	3.50	3.70	0.66	***	3.52	±	0.27	3.50	±	0.27	2.73	±	0.16	4.25	±	0.21	**	3.65	±	0.22	3.60	±	0.16

Genes and associated Affymetrix probe IDs are shown. All values are mean log2 expression levels from [38] and [39]. Standard errors (SE) are shown. SHH v Other Subgroups, and presence/absence of metastatic disease, were analysed using t-tests. Clinicogenetic groups [2] were analysed using ANOVA. *p<0.05, **p<0.01, ***p<0.001.

Back to article page

ISSN: 2051-5960

Contact us

Submission enquiries: JJM.Hoozemans@vumc.nl
General enquiries: info@biomedcentral.com